| __timestamp | Bausch Health Companies Inc. | BeiGene, Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 6930000 |
| Thursday, January 1, 2015 | 2682700000 | 7311000 |
| Friday, January 1, 2016 | 2810000000 | 20097000 |
| Sunday, January 1, 2017 | 2582000000 | 62602000 |
| Monday, January 1, 2018 | 2473000000 | 195385000 |
| Tuesday, January 1, 2019 | 2554000000 | 388249000 |
| Wednesday, January 1, 2020 | 2367000000 | 600176000 |
| Friday, January 1, 2021 | 2624000000 | 990123000 |
| Saturday, January 1, 2022 | 2625000000 | 1277852000 |
| Sunday, January 1, 2023 | 2917000000 | 1504501000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. This analysis compares BeiGene, Ltd. and Bausch Health Companies Inc. over a decade, from 2014 to 2023.
Bausch Health, a stalwart in the industry, maintained a relatively stable SG&A expense, averaging around $2.6 billion annually. However, their expenses peaked in 2023, marking a 44% increase from 2014. In contrast, BeiGene, a rising star, showcased a dramatic surge in SG&A expenses, skyrocketing from a modest $7 million in 2014 to $1.5 billion in 2023, reflecting their aggressive expansion strategy.
This stark contrast highlights Bausch Health's steady approach versus BeiGene's rapid growth trajectory, offering valuable insights into their strategic priorities and market positioning.
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights